Radial versus femoral access for orally anticoagulated patients†
Antonios G. Ziakas, MD, PhD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
The first two authors contributed equally to this work.
Search for more papers by this authorCorresponding Author
Konstantinos C. Koskinas, MD, MSc
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
The first two authors contributed equally to this work.
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA 02120Search for more papers by this authorStavros Gavrilidis MD, PhD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorGeorge D. Giannoglou MD, PhD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorStavros Hadjimiltiades MD, PhD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorIoannis Gourassas MD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorEfstratios Theofilogiannakos MD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorFotios Economou MD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorIoannis Styliadis MD, PhD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorAntonios G. Ziakas, MD, PhD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
The first two authors contributed equally to this work.
Search for more papers by this authorCorresponding Author
Konstantinos C. Koskinas, MD, MSc
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
The first two authors contributed equally to this work.
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA 02120Search for more papers by this authorStavros Gavrilidis MD, PhD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorGeorge D. Giannoglou MD, PhD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorStavros Hadjimiltiades MD, PhD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorIoannis Gourassas MD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorEfstratios Theofilogiannakos MD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorFotios Economou MD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorIoannis Styliadis MD, PhD
1 st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Search for more papers by this authorConflict of interest: Nothing to report.
Abstract
Objectives: To prospectively compare the efficacy and procedural safety of the radial versus femoral route for cardiac catheterization during uninterrupted warfarin therapy. Background: The optimal treatment strategy for cardiac catheterization in patients receiving long-term oral anticoagulation has not been defined. Increasing evidence suggests the feasibility and safety of catheterization without warfarin interruption. However, the relative safety and efficacy of the radial and femoral access in fully anticoagulated patients are unknown. Methods: Fifty-six consecutive patients on chronic warfarin treatment with international normalized ratio (INR) between 1.8 and 3.5 were randomized to undergo coronary angiography, alone, or followed by percutaneous coronary intervention (PCI), via the femoral (n = 29) or radial route (n = 27). Procedural success, in-hospital major adverse cardiac and cerebrovascular events, access-site, and bleeding complications were recorded. Results: The two groups were well balanced with similar clinical characteristics at baseline. There were no significant differences in preprocedural antiplatelet therapy or in INR levels between the radial and femoral group (2.62 ± 0.7 vs. 2.48 ± 0.6, respectively, P = 0.63). Procedural success was achieved in all femoral patients, whereas one patient in the radial group (3.7%) required crossover to femoral access. Eight patients from the femoral and 10 patients from the radial group successfully underwent PCI. Access-site complications occurred only in patients who underwent PCI: three (37.5%) in the femoral versus none in the radial group (P = 0.034). Conclusion: The radial access is as efficacious and safe as the femoral route for coronary angiography in fully anticoagulated patients, but is likely to result in fewer access-site complications in patients who also undergo PCI. © 2010 Wiley-Liss, Inc.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1 Helft G,Gilard M,Le Feuvre C,Zaman AG. Drug insight: Antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation. Nat Clin Pract Cardiovasc Med 2006; 3: 673–680.
- 2 Lip GYH,Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention. The need for consensus and a management guideline. Chest 2006; 130: 1823–1827.
- 3 Douketis JD,Johnson JA,Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin. Assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164: 1319–1326.
- 4 Kovacs MJ,Kearon C,Rodger M,Anderson DR,Turpie AG,Bates SM,Desjardins L,Douketis J,Kahn SR,Solymoss S,Wells PS. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110: 1658–1663.
- 5 Wazni OM,Beheiry S,Fahmy T,Barrett C,Hao S,Patel D,Di Biase L,Martin DO,Kanj M,Arruda M,Cummings J,Schweikert R,Saliba W,Natale A. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: Comparison of strategies of anticoagulation management in the periprocedural period. Circulation 2007; 116: 2531–2534.
- 6 Annala AP,Karjalainen PP,Porela P,Nyman K,Ylitalo A,Airaksinen JK. Safety of diagnostic coronary angiography during uninterrupted therapeutic warfarin treatment. Am J Cardiol 2008; 102: 386–390.
- 7 El-Jack SS,Ruygrok PN,Webster MW,Stewart JT,Bass NM,Armstrong GP,Ormiston JA,Pornratanarangsi S. Effectiveness of manual pressure hemostasis following transfemoral coronary angiography in patients on therapeutic warfarin anticoagulation. Am J Cardiol 2006; 97: 485–488.
- 8 Karjalainen PP,Vikman S,Niemelä M,Porela P,Ylitalo A,Vaittinen MA,Puurunen M,Airaksinen TJ,Nyman K,Vahlberg T,Airaksinen KE. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 2008; 29: 1001–1010.
- 9 Jessup DB,Coletti AT,Muhlestein JB,Barry WH,Shean FC,Whisenant BK. Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy. Catheter Cardiovasc Interv 2003; 60: 180–184.
- 10 Choussat R,Black A,Bossi I,Fajadet J,Marco J. Vascular complications and clinical outcome after coronary angioplasty with platelet IIb/IIIa receptor blockade: Comparison of transradial vs transfemoral arterial access. Eur Heart J 2000; 21: 662–667.
- 11 Jolly SS,Amlani S,Hamon M,Yusuf S,Mehta SR. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: A systematic review and meta-analysis of randomized trials. Am Heart J 2009; 157: 132–140.
- 12 Ziakas A,Klinke P,Mildenberger R,Fretz E,Williams M,Della Siega A,Kinloch D,Hilton D. Comparison of the radial and the femoral approaches in percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2003; 91: 598–600.
- 13 Helft G,Dambrin G,Zaman A, et al. Percutaneous coronary intervention in anticoagulated patients via radial artery access. Catheter Cardiovasc Interv 2009; 73: 44–47.
- 14 Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-q-wave myocardial infarction. N Engl J Med 1998; 338: 1488–1497.
- 15 Bonow RO,Carabello BA,Chatterjee K,de Leon AC Jr,Faxon DP,Freed MD,Gaasch WH,Lytle BW,Nishimura RA,O'Gara PT,O'Rourke RA,Otto CM,Shah PM,Shanewise JS; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 Focused update incorporated into The ACC/AHA 2006 Guidelines For The Management Of Patients With Valvular Heart Disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to develop guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2008; 52: e1–e142.
- 16 Ansell J,Hirsh J,Poller L,Bussey H,Jacobson A,Hylek E. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004; 126( 3 Suppl): 204S–233S.
- 17 Doyle BD,Rihal CS,Gastineau DA,Holmes DR. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention implications for contemporary practice. J Am Coll Cardiol 2009; 53: 2019–2027.
- 18 MacDonald LA,Meyers S,Bennett CL,Fintel D,Grosshans N,Syegco R,Davidson CJ. Post-cardiac catheterization access site complications and low-molecular-weight heparin following cardiac catheterization. J Invas Cardiol 2003; 15: 60–62.
- 19 Garcia DA,Regan S,Henault LE,Upadhyay A,Baker J,Othman M,Hylek EM. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008; 168: 63–69.
- 20 Agostoni P,Giuseppe GL,Zoccai B, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures: Systematic overview and meta analysis of randomised trials. J Am Coll Cardiol 2004; 44: 349–356.
- 21 Hildick-Smith DJ,Walsh JT,Lowe MD,Petch MC. Coronary angiography in the fully anticoagulated patient: The transradial route is successful and safe. Catheter Cardiovasc Interv 2003; 58: 8–10.
- 22 Lo TS,Buch AN,Hall IR,Hildick-Smith DJ,Nolan J. Percutaneous left and right heart catheterization in fully anticoagulated patients utilizing the radial artery and forearm vein: A two-center experience. J Interv Cardiol 2006; 19: 258–263.
- 23 Rubboli A,Verheugt FWA. Antithrombotic treatment for patients on oral anticoagulation undergoing coronary stenting. A review of the available evidence and practical suggestions for the clinician. Int J Cardiol 2008; 123: 234–239.
- 24 Ben-Gal Y,Weisz G,Collins MB,Genereux P,Dangas GD,Teirstein PS,Singh VP,Rabbani LE,Kodali SK,Sherman W,Leon MB,Moses JW. Dual catheter technique for the treatment of severe coronary artery perforations. Catheter Cardiovasc Interv, in press. [Epub ahead of print Jan 4, 2010].
- 25 Nair P,Roguin A. Coronary perforations. Eurointervention 2006; 2: 363–370.
- 26 Berry C,Kelly J,Cobbe SM,Eteiba H. Comparison of femoral bleeding complications after coronary angiography versus percutaneous coronary intervention. Am J Cardiol 2004; 94: 361–363.
- 27 Martin JL,Pratsos A,Magargee E,Mayhew K,Pensyl C,Nunn M,Day F,Shapiro T. A randomized trial comparing compression. Perclose Proglide and Angio-Seal VIP for arterial closure following percutaneous coronary intervention: The CAP trial. Catheter Cardiovasc Interv 2008; 71: 1–5.
- 28 Nikolsky E,Mehran R,Halkin A,Aymong ED,Mintz GS,Lasic Z,Negoita M,Fahy M,Krieger S,Moussa I,Moses JW,Stone GW,Leon MB,Pocock SJ,Dangas G. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures. A meta-analysis. J Am Coll Cardiol 2004; 44: 1200–1209.
- 29 Exaire JE,Tcheng JE,Kereiakes DJ,Kleiman NS,Applegate RJ,Moliterno DJ. Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. Catheter Cardiovasc Interv 2005; 64: 369–372.
- 30 ten Berg JM,Hutten BA,Kelder JC,Verheugt FW,Plokker HW. Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications. Circulation 2001; 103: 2042–2047.